Exploring global cfDNA fragmentomics as a biomarker in real-world patients with melanoma
Journal of Investigative Dermatology · 2026
DOI: 10.1016/j.jid.2026.01.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026. Verfasst von Daniel Rizo-Potau und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Melanoma, Biomarkers, Tumor, Skin Neoplasms, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Generalitat de Catalunya Agència de Gestió d'Ajuts Universitaris i de Recerca, European Commission, Fundacion Ramon Areces.
Abstract (Originalsprache)
Circulating cell-free DNA fragmentomics-the analysis of cell-free DNA fragment-length profiles-has been explored as a biomarker across cancers, but evidence in melanoma is limited. We conducted a longitudinal prospective study of 235 patients with American Joint Committee on Cancer stages II-IV melanoma (549 plasma samples) and 11 phenotypic high-risk healthy controls, quantifying 6 fragment-size ranges by routine capillary electrophoresis. Linear mixed-effects modeling and receiver operating characteristic analyses evaluated associations with disease status; time-dependent receiver operating characteristic and mixed-effects Cox regression assessed prognostic value in resected patients. Active-disease samples showed a fragmentation shift: enrichment and increased heterogeneity of short (20-150 bp) and short-dinucleosome (250-320 bp) fragments, with depletion of mononucleosome fragments (160-180 bp), consistent with tumor-associated nuclease/chromatin processing. Discrimination of active disease versus disease-free samples was modest (area under the curve up to 0.64), comparable with serum S100 (area under the curve 0.68) and higher than lactate dehydrogenase (area under the curve 0.60). In resected patients, 250-320 bp variability and short-fragment ratios predicted relapse-free and distant-metastasis-free survival from blood draw (hazard ratio ≈ 1.5-2.4 per 1 SD increase) after clinical adjustment, with strongest performance over ∼3-6 months. Correlations with S100/lactate dehydrogenase were weak, supporting independent biological information. Low-cost electrophoresis-based fragmentomics captures clinically meaningful shifts and provides complementary short-term prognostic information, supporting integration into higher-resolution or multimodal cell-free DNA assays for risk-adapted follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Molecular Biology Core, Biomedical Diagnostic Centre, Hospital Clínic de Barcelona, Barcelona, Spain.
- Molecular Biology Core, Biomedical Diagnostic Centre, Hospital Clínic de Barcelona, Barcelona, Spain.
- Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Biomedical Research Networking C…
Förderung
- Generalitat de Catalunya Agència de Gestió d'Ajuts Universitaris i de Recerca
- European Commission
- Fundacion Ramon Areces
- Instituto de Salud Carlos III
- Generalitat de Catalunya
Zitieren
APA
Rizo-Potau, D., Forniés-Mariné, A., Villanueva-Cañas, J. L., Aguilar, M., Sánchez-Cárdenas, C., Torres, T., Podlipnik, S., Carrera, C., Puig, S., Malvehy, J., & Puig-Butillé, J. A. (2026). Exploring global cfDNA fragmentomics as a biomarker in real-world patients with melanoma. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.01.030
Vancouver
Rizo-Potau D, Forniés-Mariné A, Villanueva-Cañas JL, Aguilar M, Sánchez-Cárdenas C, Torres T, et al. Exploring global cfDNA fragmentomics as a biomarker in real-world patients with melanoma. Journal of Investigative Dermatology. 2026. doi:10.1016/j.jid.2026.01.030
BibTeX
@article{RizoPotau2026,
author = {Rizo-Potau, Daniel and Forniés-Mariné, Anton and Villanueva-Cañas, José Luis and Aguilar, Michelle and Sánchez-Cárdenas, Cristina and Torres, Teresa and Podlipnik, Sebastian and Carrera, Cristina and Puig, Susana and Malvehy, Josep and Puig-Butillé, Joan Anton},
title = {Exploring global cfDNA fragmentomics as a biomarker in real-world patients with melanoma},
journal = {Journal of Investigative Dermatology},
year = {2026},
doi = {10.1016/j.jid.2026.01.030}
}
EUVIMED